← SynDRA
AZD-5153
SynDRA canonical compound SYN0039256 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | BRD4 | E2F | MTOR | MYC |
|---|
| Mechanism of action | bromodomain inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BET bromodomain inhibitor
- BRD4 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- BRD2
- BRD3
- BRD9
- BRDT
- CCL2
- CREBBP
- EP300
- TAF1
- TAF1L
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- HLAB
- IFNB1
- KSYK
- NSD2
- PARP1
- SYK
Cross-references
Synonyms
- AZD 5153
- AZD5153
- RSMYFSPOTCDHHJ-GOSISDBHSA-N
- UNII-C7C7U6YEAO
- C7C7U6YEAO
- SCHEMBL17477306
- MolPort-044-561-768
- AZD 5153 [WHO-DD]
- EX-A1317
- BCP20057
- ZINC575441177
- AKOS030627661
- SB18713
- AS-35242
- J3.544.368A
- (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one
- XNH
- 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-
- (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe
- RefChem:116007
- MFCD30530420
- orb2279152
- CHEBI:231674
- C25H33N7O3
- AZD5153, 6-hydroxy-2-naphthoate
- BDBM50260093
- NSC797938
- T3504L
- AZD-5153, 6-hydroxy-2-naphthoate
- NSC-797938
- NCGC00510269-02
- AC-31599
- DA-50855
- HY-100653
- CS-0019891
- (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one
- CCG-270353
- AZD5153 (6-Hydroxy-2-naphthoic acid)
- DA-61377
Look up AZD-5153 in the interactive SynDRA portal →